Comprehensive Senolytic Protocol 2026

Protocol Overview

Senolytic intervention has evolved dramatically since the original Mayo Clinic D+Q protocols. This 2026 protocol combines three mechanistically distinct senolytic approaches plus immune support:

1. Direct senolysis — Quercetin (BCL-xL inhibition)
2. Natural multi-mechanism senolysis — Fisetin (PI3K/AKT, BCL pathways)
3. Immune-mediated indirect senolysis — SGLT2 inhibitor (PD-L1 downregulation)
4. Immune function support — Urolithin A (mitochondrial function in immune cells)

This is the most comprehensive senolytic protocol available in 2026.

The Three Senolytic Mechanisms

Why Three Mechanisms?

Senescent cells are heterogeneous. Different subpopulations:

• Use different pro-survival pathways
• Express different surface markers
• Reside in different tissues
• Have different susceptibility to clearance

Single-mechanism senolytics clear some senescent cell subpopulations effectively but miss others. Three-mechanism approach addresses heterogeneity.

The Evidence Foundation

Direct senolysis (Quercetin):

• Mayo Clinic D+Q protocols (Hickson 2019, Justice 2019, Gonzales 2023)
• February 2025 Alzheimer's risk trial (eBioMedicine)
• Mechanism: BCL-xL inhibition triggers senescent cell apoptosis

Natural senolysis (Fisetin):

• Yousefzadeh et al. (EBioMedicine, 2018) — strongest natural senolytic in screening
• Mechanism: PI3K/AKT modulation, BCL pathway effects, autophagy
• Stronger natural senolytic activity than Quercetin alone

Indirect immune-mediated (SGLT2):

• Katsuumi et al. (Nature, 2024) — PD-L1 downregulation on senescent cells
• Zhang et al. (Cell Reports Medicine, 2025) — granzyme B elevation, 90.5% telomere lengthening
• Different mechanism from direct senolytics — restores immune surveillance

Immune support (Urolithin A):

• 2025 MitoImmune trial (Nature Aging) — improved immune cell function
• Enhances NK cell and T cell capacity
• Supports clearance of senescent cells revealed by SGLT2

Component 1: Quercetin (Direct Senolytic)

Dose: 1250mg × 2 consecutive days, monthly cycling Form: Quercetin Phytosome (Quercefit) or EMIQ Timing: With fatty meal for absorption

Why bioavailability-enhanced form:

• Standard Quercetin has ~1% bioavailability
• Phytosome and EMIQ forms 20× better absorbed
• Critical for achieving senolytic plasma concentrations

With Dasatinib (if physician access):

• Add Dasatinib 100mg on each of 2 dosing days
• Substantially enhances senolytic activity
• The original D+Q protocol
• Requires prescription

Without Dasatinib:

• Quercetin alone has weaker but measurable senolytic effect
• Augmented by Fisetin combination in this protocol
• Acceptable approach when prescription unavailable

Component 2: Fisetin (Natural Multi-Mechanism Senolytic)

Dose: 1000mg × 3 consecutive days, monthly cycling Form: Liposomal or standardised extract Timing: With fatty meal

Why fisetin:

• Strongest natural senolytic in published screening studies
• OTC, no prescription required
• Mechanism complementary to Quercetin (multiple pathways)
• Acceptable as Dasatinib substitute when needed

Stagger from Quercetin:

• Schedule Quercetin days 1-2 of month
• Schedule Fisetin days 15-17 of month
• This provides two senolytic pulses monthly with different mechanisms
• Reduces overall side effect burden vs same-day combination

Component 3: SGLT2 Inhibitor (Immune-Mediated Senolytic)

Drug: Dapagliflozin or Empagliflozin Dose: 5-10mg daily continuous Timing: Morning, with or without food

Mechanism rationale:

• AICAR upregulation downregulates PD-L1 on senescent cells
• "Reveals" senescent cells to immune surveillance
• Cytotoxic T cells and NK cells then clear them
• Different from direct senolytic killing

Why daily continuous:

• Mechanism requires sustained immune surveillance enhancement
• Cannot be effectively pulsed like direct senolytics
• Aligns with established T2D and CV outcome trial dosing

Prescription required:

• This component requires physician access
• Off-label for non-diabetic longevity use
• Insurance coverage variable

Component 4: Urolithin A (Immune Function Support)

Dose: 500mg daily continuous Form: Mitopure (Timeline) — the clinically validated form Timing: Morning with or without food

Mechanism rationale:

• Improves mitochondrial function in immune cells
• Enhances NK cell and T cell cytotoxic capacity
• Restores immune surveillance function with age
• Synergistic with SGLT2 immune surveillance mechanism

Why include:

• 2025 MitoImmune trial established direct immune benefits
• Amplifies effects of SGLT2-mediated PD-L1 changes
• Independent benefits for mitochondrial health

Cost consideration:

• Premium-priced ($60-90/month for 500mg)
• Optional based on budget
• Other Urolithin A forms exist but less clinical validation

The Complete Protocol Schedule

Daily continuous:

• Dapagliflozin 5-10mg (morning)
• Urolithin A 500mg (morning)
• Foundation longevity supplements (Omega-3, etc.)

Monthly pulsed schedule:

Days 1-2 (Quercetin pulse):

• Quercetin Phytosome 1250mg with fatty meal
• (± Dasatinib 100mg if physician access)
• Continue continuous components

Days 3-14: Continuous components only

Days 15-17 (Fisetin pulse):

• Fisetin 1000mg with fatty meal
• Continue continuous components

Days 18-30: Continuous components only

Repeat monthly

Prerequisites

This is an advanced protocol requiring:

• Adults 50+ (senescent cell accumulation age-dependent)
• Established baseline longevity care
• Physician access for SGLT2 prescription
• Sufficient resources for premium components
• Established work with longevity-focused practitioner ideal

Required baseline:

• Complete metabolic panel
• Lipid panel, hs-CRP, IL-6
• CBC with differential
• Kidney function (eGFR must be >30)
• Liver function
• Baseline body composition

Contraindications:

• Active pregnancy or breastfeeding
• Active cancer (senolytic effects on cancer biology complex)
• Active major infection
• Severe renal impairment
• Recurrent infections (UTI, genital)
• Frailty syndrome (less studied)
• Type 1 diabetes (DKA risk with SGLT2)

Monitoring Schedule

Month 1:

• Tolerability assessment (especially SGLT2 adaptation)
• First Quercetin and Fisetin pulses observed
• Side effect tracking

Month 3:

• Complete metabolic panel
• hs-CRP, IL-6
• CBC
• Side effect review
• Adjustment if needed

Month 6:

• Complete labs
• Consider biological age markers
• Body composition reassessment
• Continue, modify, or escalate

Annually:

• Comprehensive panel
• Telomere length (if accessible — TruDiagnostic, Life Length)
• Biological age (GlycanAge, DunedinPACE)
• DEXA scan
• Physician review

Expected Effects Timeline

Month 1:

• SGLT2 adaptation effects (mild fatigue, possible thirst)
• First senolytic pulses with possible mild fatigue
• Minor inflammation marker improvements

Months 1-3:

• Measurable hs-CRP reductions
• Subjective energy improvements
• Possible improved exercise recovery
• Metabolic improvements (HbA1c, lipids)

Months 3-6:

• More substantial inflammatory marker improvements
• Cardiovascular biomarker changes
• Body composition improvements
• Possible telomere changes emerging (per Zhang 2025 timeline)

Months 6-12:

• Cumulative immune restoration
• Long-term cardiovascular protection
• Possible biological age marker improvements
• Stabilisation of improved state

Cost Analysis

Annual cost estimate (US pricing 2026):

Premium intervention. Reflects 2026 senolytic landscape pricing.

Budget Alternative

For those unable to access full protocol, simplified version:

Reduced protocol:

• Fisetin 1000mg × 3 days monthly (~$150-300/year)
• Quercetin 1000mg × 2 days monthly (basic form, ~$50-100/year)
• Berberine 1500mg daily (replacing SGLT2, ~$200-500/year)
• Metformin 500mg twice daily if available (~$50-200/year)
• Total: $250-1,100/year

Provides direct natural senolytic effects + AMPK activation. Less comprehensive but accessible.

What This Protocol Won't Do

Realistic expectations:

• Will not reverse aging dramatically in short term
• Will not eliminate need for healthy lifestyle (foundation matters)
• Will not clear all senescent cells (clearance is partial)
• Will not produce dramatic short-term subjective changes
• Results are gradual and cumulative
• Senescent cells regenerate; clearance must be ongoing

This protocol provides comprehensive senolytic intervention based on 2026 evidence — but it's a component of broader longevity strategy, not a standalone solution.

Integration with Other Protocols

Compatible with:

• NAD+ optimisation (NMN or NR + TMG) — supports sirtuin function
• Cardiovascular longevity stack (CoQ10, Omega-3, Astaxanthin)
• Hormonal optimisation as appropriate
• Gut-metabolic protocols (Akkermansia, polyphenols)

Coordinate carefully:

• Rapamycin — careful monitoring, both modulate immune function
• GLP-1 agonists — synergistic but careful supervision
• Heavy resistance training — recovery may be affected by senolytic pulses

Side Effect Management

SGLT2-related:

• Genital mycotic infections (most common, 5-15%)
• Standard antifungal treatment usually sufficient
• Prevention: hygiene, hydration

Quercetin pulse-related:

• Possible transient fatigue on dosing days
• Mild GI effects
• Schedule pulses on lower-activity days

Fisetin pulse-related:

• Similar profile to Quercetin
• Generally well-tolerated

Urolithin A:

• Excellent tolerability
• No common side effects at standard doses

Adjustments by Individual Response

Excellent response:

• Inflammation markers reduced
• Subjective improvements
• Continue protocol
• Consider biological age tracking

Partial response:

• Verify adherence
• Consider dose optimisation
• Evaluate lifestyle factors
• May add additional support

Limited response:

• Detailed workup
• Address underlying factors (sleep, stress, nutrition)
• Reassess after 3 additional months

Adverse effects:

• Address specific issues
• Component reduction where appropriate
• Continue compatible components

Who Is This Protocol For?

Strong candidates:

• Adults 50+ with confirmed metabolic or cardiovascular risk
• Family history of accelerated aging-related disease
• Established baseline longevity practice
• Resources for premium intervention
• Working with longevity physician

Reasonable candidates:

• Adults 45+ seeking advanced longevity intervention
• Those plateaued on simpler approaches
• Chronic inflammation despite lifestyle optimisation

Not appropriate for:

• Young, healthy adults under 45
• Active cancer or recent treatment
• Severe immunocompromise
• Pregnancy/breastfeeding
• Active infections
• Severe renal impairment

The 2026 Senolytic Field Position

This protocol represents current best evidence for comprehensive senolytic intervention. The field continues to evolve:

Ongoing developments:

• UBX1325 (Unity Biotechnology) — selective senolytic for diabetic macular edema
• New direct senolytic compounds in development
• Tissue-specific senolytic strategies
• Personalised senolytic protocols based on senescent cell profiling

The protocol will likely be refined or superseded by 2027-2028 as new evidence emerges. For current best evidence-based comprehensive senolytic intervention, this 4-component approach represents 2026 state-of-the-art.

Related Research

• The Senolytic Stack 2026: Quercetin + Fisetin + SGLT2 Combined Protocol
• SGLT2 Inhibitors: The First Drugs That Reverse Telomere Aging in Humans
• Urolithin A and the Immune System: The 2025 MitoImmune Trial Results